Special Issue "New Advance in Immuno-Oncology"
Deadline for manuscript submissions: closed (31 October 2023) | Viewed by 18223
Immune system plays an important role in tumor development, acting by means of both innate and adaptive immunity. The immune surveillance mechanism is a dynamic process characterized by three phases: Elimination, Equilibrium and Escape. Thus, the immune system not only protects against cancer development but also shapes emerging tumors. T cells are able to recognize tumor associated antigens as non-self. The CD8+ T lymphocytes act releasing cytotoxic granules, while CD4+ T cells release substances promoting proliferation and lymphocytes activation. The chronic stimulation of immune system due to the continuous release of antigens, leads to the amplification of negative feedback, such as the lymphocytes exhaustion, the immune checkpoint activation or the T regulatory cells attraction. Moreover, the cancer cells could express molecules inhibiting the immune response, such as PD-L1. Recent studies demonstrated the association between immune cells infiltration of tumor tissue or circulating immune cells and prognosis or response to anticancer treatment in various cancer types. Moreover, different anticancer treatment, including target therapy, chemotherapy and radiotherapy, are able to modify patients’ immune-fitness.
This Special Issue “ New Advance in Immuno-Oncology ” will include reviews and original research focusing on the role of the immune system in tumour development, on predictive or prognostic immune biomarkers identification, and on new treatments in immuno-oncology field in all types of solid tumor.
Dr. Concetta Elisa Onesti
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomedicines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- immune system and cancer